PTO Grants Additional Reviews of Herceptin Patents after Hospira Challenges

Drug Industry Daily
A A
The PTO’s Patent Trial and Appeal Board will evaluate the validity of three Genentech patents covering its blockbuster breast cancer treatment Herceptin, following petitions for inter partes review filed by Hospira.

To View This Article:

Login

Subscribe To Drug Industry Daily